Dugel Pravin sold $233K of OCUL
Dugel Pravin (See Remarks) sold 21,649 shares of OCULAR THERAPEUTIX, INC (OCUL) at $10.77 ($0.23M total) on 2026-08-24 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is the first public report of this transaction, providing new data for investors monitoring insider activity.
Market read
Provides fresh insider‑sale information; modest relevance for short‑term traders.
What to watch
Potential upcoming clinical data releases could offset any short‑term sell pressure.
Background
Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑scheduled sales.
Ticker impact
Officer/director Dugel Pravid sold 21,649 shares for $233K via a 10b5‑1 plan, reducing his stake to 2.5M shares.
Minor downward pressure, likely within normal volatility range.
Sale size is modest relative to total holdings and market cap; executed under a pre‑arranged plan, so no strong directional implication.
Market effects
None significant for the ophthalmology biotech sector.
No regional effect.
Limited to OCUL shareholders.
Counterpoint
The sale could be a routine liquidity event, not a negative signal.
Key entities
- CompanyOCULAR THERAPEUTIX, INC.
NASDAQ‑listed ophthalmology biotech.
- InsiderDugel Pravin
Officer and director of OCUL.
